Pharmacopeia Drug Discovery, Inc. (PCOP)

[surf1944]

Pharmacopeia to Present Highlights From the Company's DARA Program at the Tenth International Conference on Endothelin (ET-10)

PRINCETON, N.J., Sept. 5 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced that David M. Floyd, Ph.D., the Company's Executive Vice President and Chief Scientific Officer, will present highlights of Pharmacopeia's DARA program at the Tenth International Conference on Endothelin (ET-10). The conference will be held September 16-19, 2007, at the Centro Congressi Giovanni XXIII in Bergamo, Italy.

Dr. Floyd's presentation will take place during Session 11 - Emerging Targets on Wednesday, September 19th at 2 p.m. local time. A brief question and answer session will immediately follow the presentation. The presentation may be accessed after the event from the News & Events page on the Pharmacopeia website at http://www.pharmacopeia.com.

Pharmacopeia's lead internal program is a dual-acting angiotensin and endothelin receptor antagonist (DARA) that is being developed as a potential treatment for hypertension and diabetic nephropathy. PS433540, the first and only DARA compound in development, selectively blocks the action of two potent vasoconstrictor and mitogenic agents, angiotensin II (AII) and endothelin 1 (ET1), at the AII receptor sub-type 1 and the ET receptor sub-type A, respectively. As such, PS433540 combines the properties of an angiotensin receptor blocker (ARB) and an endothelin receptor antagonist (ERA) in the same orally bioavailable small molecule.